Substituted pyridazines having cytokine inhibitory activity

A compound of the formula

• wherein
• A is halogen, phenyl, S(O)m phenyl, or NR5R6;
• R1 is hydrogen, NH(C1-C6 alkyl)aryl, NH(C1-C6 alkyl) or NH(C3-C6 cycloalkyl), said aryl group being optionally substituted by 1-3 groups selected from halogen, hydroxy, CF3, NH2, and NO2;
• R2, R3 and R4 independently represent a member selected from the group consisting of hydrogen, halogen, hydroxy, CF3, NH2, NO2, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl or phenyl;
• R5 and R6 are independently hydrogen, C1-C6 alkyl, (C1-C6 alkyl)—O—(C1-C6 alkyl), (C1-C6 alkyl)cycloalkyl, (C1-C6 alkyl) NR7R8, C1-C6 alkylphenyl, said phenyl group optionally substituted with 1 to 3 groups selected from (C1-C6 alkyl) or (C1-C6 alkoxy);
• (C1-C6 alkyl)—NHCOO—(C1-C6 alkyl), (C1-C6 alkyl)C≡C, (C1-C6 alkyl)indole, (C1-C6 alkyl)pyridinyl, a pyrrolidinyl or piperidyl group, said groups optionally substituted with C1-C6 alkyl or benzyl;
• or
• R5 and R6 are taken together with the nitrogen atom to form an optionally substituted 4 to 10 membered mono, bicyclic or azabicyclic heterocyclic ring containing at least one N atom, and optionally containing 1-2 additional N atoms and 0-2 O or S atoms, said ring optionally substituted by 1-3 groups selected from C1-C6alkyl, OH, O(C1-C6 alkyl), COO(C1-C6 alkyl), C1-C6alkyl benzodioxole, CONR7R8, phenyl, said phenyl group optionally substituted with halogen, C1-C6alkyl, C1-C6 alkoxy;
• CH(aryl)2, said aryl optionally substituted with 1-3 groups selected from C1-C6alkyl, OH or halogen;
• NR7R8;
• R7 and R8 are independently hydrogen, C1-C6 alkyl, (C1-C6 alkyl)—O—(C1-C6 alkyl), C1-C6 alkylaryl, (C1-C6 alkyl)—NHCOO—(C1-C6 alkyl), COO—(C1-C6 alkyl), a pyrrolidinyl or piperidyl group, said groups optionally substituted with C1-C6 alkyl or C1-C6 alkylaryl;
• or
• R7 and R8 are taken together with the nitrogen atom to form an optionally substituted 4 to 10 membered mono, bicyclic or azabicyclic heterocyclic ring containing at least one N atom, and optionally containing 1-2 additional N atoms and 0-1 O or S atoms, said ring optionally substituted by 1-3 groups selected from C1-C4alkyl, OH, O(C1-C6 alkyl),
• Q is N;
• m is 0, 1 or 2;
• or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof.